Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM3C8GQ)

Drug Name

PF-489791 Drug Info

Synonyms

UNII-2S27T3DSZ3; PF-489791; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Phase 2	[1]
Raynaud disease	BD42.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 11465695
CAS Number: CAS 853003-48-2
TTD Drug ID: DM3C8GQ

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Phosphodiesterase 5A (PDE5A)	DTT	PDE5A	3.632	3	3.632	4.271

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Chronic obstructive pulmonary disease

ICD Disease Classification

CA22

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Phosphodiesterase 5A (PDE5A)	DTT	PDE5A	1.60E-01	-0.25	-0.99

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025495)
2	Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.